Trastuzumab activates allogeneic or autologous antibody-dependent cellular cytotoxicity against malignant rhabdoid tumor cells and interleukin-2 augments the cytotoxicity. [electronic resource]
Producer: 20080603Description: 1192-9 p. digitalISSN:- 1078-0432
- Antibodies, Monoclonal -- pharmacology
- Antibodies, Monoclonal, Humanized
- Antibody-Dependent Cell Cytotoxicity
- Antineoplastic Agents -- pharmacology
- Blotting, Western
- Cell Line, Tumor
- Female
- Flow Cytometry
- Fluorescent Antibody Technique
- Humans
- Immunohistochemistry
- Infant
- Infant, Newborn
- Interleukin-2 -- pharmacology
- Leukocytes, Mononuclear -- immunology
- Male
- Receptor, ErbB-2 -- biosynthesis
- Reverse Transcriptase Polymerase Chain Reaction
- Rhabdoid Tumor -- immunology
- Trastuzumab
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.